Curated Selection of the Latest Developments in the Field of New Drug Research and Development: A Quick Overview of Progress in New Drug R&D, Pharmaceutical Deals, and Cutting-Edge Technologies from This Week.

Initial enrollment of patients with stomach and esophageal cancer has begun for a second-stage mixed studies trial, utilizing Affibody's ABY-025 diagnostic tool for positron emission tomography.

On March 22, Johnson & Johnson announced FDA approval of OPSYNVI®, their new drug for treating WHO Group 1 PAH and class II-III PAH in adults. OPSYNVI® combines macitentan and tadalafil in a single tablet.

Corteria Pharmaceuticals has launched the first stage of clinical trials to assess the efficacy of their CRF2 activator, COR-1167, specifically targeting the progression of cardiac insufficiency.

Levocetirizine is a small, powerful drug that works as an H1 receptor antagonist to treat various allergies, including respiratory issues, dermatitis, and eczema.

Intravacc, a globally recognized pioneer in the field of translational research as well as the creation of vaccines for both prevention and treatment, has shared encouraging results from initial human trials of Avacc 10.

Bioequivalence is a pharmacological term used to describe the similarity in the pharmacokinetic profiles of two drug products, usually a brand-name drug and a generic drug.

Aptamer Sciences Submits New Drug Application for Groundbreaking Hepatocellular Carcinoma Therapy AST-201: A Potential Solution for Unmet Treatment Requirements.

Nortriptyline, a monoamine reuptake inhibitor, is a small molecule drug that exhibits its pharmacological action by targeting MATs.

Novo Nordisk has entered into an acquisition agreement with Cardior Pharmaceuticals, with the deal amounting to a maximum of 1.025 billion Euros.

Bioavailability refers to the extent and rate at which the active ingredient of a drug or nutrient is absorbed into the circulation and becomes available at the site of action within the body.

Apogee Therapeutics has initiated dosing of initial volunteers in a Phase 1 study of their new extended-duration IL-4Rα antibody, APG808, aimed at managing Chronic Obstructive Pulmonary Disease (COPD) and various inflammatory conditions.